Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous rituximab (Subcutaneous MabThera)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSubcutaneous formulation of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionAntibody
Latest Stage of DevelopmentRegistration
IndicationNon-Hodgkin's lymphoma (NHL)
Partner

Chugai Pharmaceutical Co. Ltd.; Genentech Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today